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Summary 
Human melanoma MZ2-MEL expresses several distinct antigens that are recognized by autologous 
cytolytic T lymphocytes (CTL). Some of these antigens are encoded by genes MAGE-1, MAGE-3, 
and BAGE, which are expressed in a large fraction of tumors of various histological types but 
are silent in normal adult tissues with the exception of testis. We report here the identification 
of the gene coding for MZ2-F, another antigen recognized by autologous CTL on MZ2-MEL 
cells.  This gene,  which was named GAGE-l,  is not related to any presently known  gene.  It 
belongs to a family of genes that are expressed in a variety of tumors but not in normal tissues, 
except for the testis. Antigenic peptide YILPRPRRY, which is encoded by GAGE-l, is recognized 
by anti-MZ2-F CTL on class I molecule HLA-Cw6. The two genes of the GAGE family that 
code for this peptide, namely GAGE-1  and GAGE-2, are expressed in a significant proportion 
of melanomas (24%), sarcomas (25%), non-small cell lung cancers (19%), head and neck tumors 
(19%), and bladder tumors (12%). About 50% of melanoma patients carry on their tumor at 
least one of the presently defined antigens encoded by the MAGE, BAGE,  and GAGE genes. 
H 
uman melanoma cells bear antigens that are recognized 
CD8 +  be derived ei-  by autologous  CTL, which can 
ther from blood lymphocytes or from tumor-infiltrating lym- 
phocytes (1). Two distinct strategies have been used to char- 
acterize these antigens. The first is a genetic approach based 
on transfection of genomic or cDNA libraries to identify the 
gene encoding the antigen (2-7). The antigenic peptide can 
then be identified on the basis of the protein sequence encoded 
by the gene (6, 8-12). The second approach involves acid elu- 
tion of peptides from immunoprecipitated  HLA molecules 
followed by separation  of the peptides,  evaluation of their 
ability to sensitize target cells to CTL,  and sequencing of 
the active peptide (13,  14). 
A first class of antigens that are recognized on melanoma 
by autologous CTL is encoded by genes that are expressed 
in various tumors but that  are completely silent in normal 
adult  tissues,  except  the  testis.  These  genes include  genes 
MAGE-1, MAGE-3, and BAGE (2, 6, 9, 11, 15). The mouse 
gene P/A, which codes for a tumor rejection antigen of mouse 
tumor P815, follows the same pattern of expression (16). The 
tumor specificity of these antigens may make them targets 
of choice for cancer immunotherapy based on specific immu- 
nization. 
A  second class  of antigens represents  differentiation  an- 
tigens encoded by genes that are expressed in melanoma and 
in normal mdanocytes. Antigens derived from tyrosinase were 
the first examples of this class, which also comprises antigens 
encoded by Melan-A ~ART-1, gplOOmet17, and gp75  TRPI (3, 4, 
7,  10,  12,  13,  17,  18). 
We report here the identification of a new member of the 
first class  of tumor  antigens. 
Materials and Methods 
Cell Lines.  Melanoma cell line MZ2-MEL was derived from 
an abdominal metastasis of patient MZ2 and a number of subdones 
were obtained. Subdone MZ2-MEL.3.0 was obtained by limiting 
dilution. Subline MZ2-MEL.3.1 was obtained by extending the cul- 
ture of subclone MZ2-MEL.3.0  for more than  150 generations. 
Subline MZ2-MEL.43 was derived by limiting dilution from MZ2- 
MEL.3.0 cells that had survived to a mutagen treatment (19, 20). 
Clonal subline M7_2-MEL.4, which does not express antigen MZ2-F, 
was selected in vitro from subline MZ2-MEL.3.1 with autologous 
anti-MZ2-F CTL clone 76/6 (20). MZ2-E-negative donal subline 
MZ2-MEL.2.2 was sdected from subline MZ2-MEL3.1 with an 
autologous anti-MZ2-E CTL clone (20). MZ2-MEL2.2 was fur- 
ther treated in vitro with anti-MZ2-F CTL done 76/6 and clonal 
subline MZ2-MEL.2.2.5,  which does not express antigen MZ2-F 
was obtained. Melanoma ceU lines were grown as previously de- 
scribed (20, 21). Autologous CTL clone 76/6 was derived from 
PBL of patient MZ2 by in vitro stimulation  with irradiated MZ2- 
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EBV were derived from the PBL of patients MZ2 and LB33 by 
standard techniques.  IGR3-MEL, a melanoma line derived from 
an HLA-Cw6 patient (22), was kindly provided by Dr. D. Rimoldi 
(Ludwig Institute for Cancer Research,  Lausanne,  Switzerland). 
HeLa-S3 cells were obtained from the American Type Culture Col- 
lection. They were cotransfected by the calcium phosphate precipi- 
tate method with the GAGE.1 cDNA cloned in plasmid PeDNA3 
(InVitrogen, San Diego, CA), which contains the neomycin resis- 
tance gene, and with the HLA-Cw*0601 cDNA cloned in plasmid 
pcDNAI/Amp (InVitrogen). A clonal subline  was isolated  from 
a G418-resistant  transfected population. 
Lysis Test.  Lytic activity of CTL was tested in chromium re- 
lease assays as previously described (23). We used indifferently as 
positive control target MZ2-MEL.43 (see Fig. 1) or MZ2-MEL.3.1 
(see Fig.  6).  Negative control target was MZ2-MEL.4. 
Construction of the cDNA Library.  Poly-A + RNA was extracted 
from MZ2-MEL.43 cells using mRNA extraction kit FasTrack (In- 
Vitrogen). mRNA was converted to cDNA with the Superscript 
Choice System (GIBCO BILL, Gaitbersburg, MD) using an oligo- 
dT primer containing a NotI site at its 5' end. cDNA were then 
ligated to BstXI adaptors and digested with NotI. After size frac- 
tionation, the cDNA were unidirectionally cloned into the BstXI 
and NotI sites of plasmid pcDNAI/Amp. Recombinant plasmids 
were electroporated into Escherichia coli DH5-c~ and selected with 
ampicillin  (50/~g/ml). The library was divided into 1,500 pools 
of'~100 cDNA clones. Each pool of  bacteria was amplified to satu- 
ration, and plasmid DNA was extracted by a simplified  alkaline 
lysis method without phenol extraction (24). 
Transfection of COS-7 Cells.  Transfection experiments were per- 
formed by  the  DEAE-dextran-chloroquine  method  (3,  4,  25). 
Briefly, 1.5  x  104 COS-7 cells were transfected with '~100 ng of 
plasmid DNA of a pool of the cDNA library and either 30 ng of 
plasmid pcD-SRot (26) containing the HLA-AI gene (27), 50 ng 
of plasmid  pcDNAI/Amp containing the autologous HLA-B37 
cDNA, or 75 ng of plasmid pcDNAI/Amp containing the autolo- 
gnus HLA.Cw*0601  cDNA. The HLA-AI gene, derived from an- 
other patient, was  kindly provided by Dr. Girdlestone (Medical 
Research Council Centre, Hills Road, Cambridge, UK). The HLA- 
B37 and the HLA-Cw*0601  cDNA derive from patient MZ2 and 
were isolated from the cDNA library described above by hybrid- 
ization with specific oligonucleotides.  Transfected COS-7 cells were 
tested in a CTL stimulation assay after 24-48 h. The data shown 
in Figs. 2 and 7 were obtained by transfecting 100 ng of the HLA- 
Cw*0601 construct with 100 ng of the GAGE cDNA, and by test- 
ing the transfected COS-7 cells after 24 h. 
CTL Stimulation Assay.  Transfectants were tested for their ability 
to stimulate the production of TNF by the CTL as described (21). 
Briefly, 3,000 CTL were added to microwells containing transfected 
cells in 100/~1 of Iscove's modified Dulbecco's medium (GIBCO 
BRL) containing 10% human serum and 30 U/ml rhIb2. After 
18 h, the supernatant was collected and its TNF content was de- 
termined by testing its cytotoxic effect on WEHI  164 clone 13 
cells (28) in a 3-[4,5-dimethylthiozol-2-yl]-2,5-diphenyl-tetrazolium 
bromide (MTT) colorimetric assay (21, 29). Positive control stimu- 
lator cells were indifferently MZ2-MEL.3.1 (see Fig. 2) or MZ2- 
MEL.43 (see Fig. 7). Negative control stimulator cells were MZ2- 
MEL.2.2.5. The inhibition with mAb W6/32 (30) was performed 
by addition of a 1/20 dilution of W6/32 ascites to the CTL stimu- 
lation assay. 
DNA Sequence Analysis.  DNA sequencing was performed by 
the dideoxy-chain termination method (T7 Sequencing Kit; Phar- 
macia LKB, Uppsala Sweden and ATaqTMCycle-Sequencing Kit; 
U.S. Biochemical Corp., Cleveland,  OH) using specific oligonu- 
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cleotides as primers. The computer search for sequence homology 
was done with program blast @ncbi.nlm.nih.gov.  Sequence align- 
ments were performed with Geneworks  |  software (Intelligenetics, 
Mountain View,  CA). 
Northern  Blot Analysis.  Total  RNA  was  isolated  by  the 
gnanidineqsothiocyanate  procedure as described (31). Northern blots 
were prepared as described (16) and were hybridized with  32p. 
labeled cDNA 2D6. The membranes were washed twice for 5 min 
at room temperature in 2 x  SSC and twice for 15 rain at 60~ 
in 2 x SSC supplemented with 1% SDS, and were autoradiographed 
overnight. Control hybridization was performed on the same mem- 
brane with a mouse tS-actin probe. 
PCR Assay  for the Expression of GAGE Genes.  Total RNA was 
extracted by the guanidine-isothiocyanate procedure as described 
(31). Reverse transcription was performed on 2/~g of total RNA 
in a reaction volume of 20/~1 with 4/~1 of 5 x  reverse transcriptase 
buffer (GIBCO BILL), 1/zl each of 10 mM deoxynucleotides, 2 
/zl of a 20-/zM  solution of oligo(dT)ls primer, 20 U  of RNasin 
(Promega Biotech, Madison, WI), 2/zl of 0.1 M dithiotreitol, and 
200 U  of Moloney murine leukemia virus reverse transcriptase 
(GIBCO BRL). The reaction was incubated at 42~  for 60 min. 
1/20 of the cDNA product was then supplemented with 5/zl of 
10 x  thermostable DNA polymerase buffer (Finnzymes OY, Espoo, 
Finland),  1/~1 each of 10 mM dNTP, 2 #1 each of 20-/~M primer 
solutions, 1 U of DynaZyme  TM (Finnzymes OY), and water to a 
final volume of 50/zl. The PCR primers for the amplification of 
all GAGE genes were either 5'-GCGGCCCGAGCAGTTCA-3' 
(VDE43, sense, nucleotide 126--142)  or 5'-AGACGCTACGTAGAG- 
CCT-Y (VDE18, sense, nucleotide 88-105), as indicated, and anti- 
sense primer  5'-CCATCAGGACCATCTTCA-Y (VDE24,  anti- 
sense, nucleotide 309-326).  For the specific amplification of GAGE-I 
and  GAGE-2,  sense primer  5'-GACCAAGACGCTACGTAG-Y 
(VDE44, sense, nudeotide 83-100) was used with antisense primer 
VDE24. A first denaturation step was done for 5 min at 94~ 
30 cycles were then performed as follows:  1 min at 94~  2 min 
at 56~  (55~  when primer VDE18 was used), and 3 min at 72~ 
A final extension step of 15 min at 72~  was done. 10-/zl aliquots 
of the PCR products were size separated  on agarose  gels. RNA 
integrity was checked by reverse transcription and amplification 
of the B-actin mRNA. 
Production of Truncated  GAGE-1 cDNA.  Progressive 3' deletions 
were produced with the Erase-a-Base System (Promega) as described 
(11). A minigene containing the first 118 nucleotides of GAGE-1 
was constructed by PCK using specific primers and was cloned 
in plasmid  pcDNA3. 
Antigenic Peptides and CTL Assay.  Peptides were synthesized 
on solid phase using F-moc for transient  NH2-terminal protection, 
as described by Atherton et al., and they were characterized by mass 
spectrometry (32). All peptides were >90% pure as indicated by 
analytical HPLC. Lyophilized peptides were dissolved at 20 mg/ml 
in DMSO, diluted at 2 mg/ml in 10 mM acetic acid, and stored 
at  -80~  Peptides were tested in CTL stimulation assays with 
COS-7 cells transfected with HLA-Cw*0601  and incubated with 
the peptides. They were also tested in chromium release assays, where 
1,000 SlCr-labeled target cells were incubated for 30 min at 37~ 
in 96-well microplates with various concentrations of peptide be- 
fore addition of CTL 76/6 at a lymphocyte/target ratio of 10:1. 
The assay was  terminated after a 4-h incubation at 37~ 
l~esu|t$ 
A  panel  of stable autologous  CTL clones was  obtained 
against  the human melanoma cell line MZ2-MEL by stim- 
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tumor cells (19). Tumor cell variants selected in vitro for 
resistance  to some of these CTL clones remained sensitive 
to others, indicating that several  different antigens were present 
on the MZ2-MEL cells (20). One of these antigens, named 
MZ2-F, was recognized by CD8 + CTL done 76/6, which 
lysed autologous MZ2-MEL cells, but neither autologous 
EBV-B cells nor NK target K562 cells (Fig. 1). Upon con- 
tact with MZ2 melanoma cells, this CTL clone released TNF, 
and this was inhibited by an mAb directed against HLA class 
I molecules (Fig.  2). 
Identification of  a eDNA Encoding  Antigen MZ2-E  To clone 
the gene encoding antigen MZ2-F, we used KNA from MZ2- 
MEL to prepare a eDNA library with plasmid pcDNAI/Amp. 
This plasmid contains the origin of replication of SV40 
resulting in considerable  episomal multiplication in COS-7 
cells and therefore high expression of doned genes (25). To 
allow presentation of the antigen to CTL, COS cells must 
express the appropriate HLA molecule, and this can be achieved 
by cotransfection of the relevant gene (3, 4). A prerequisite 
for this method is therefore the knowledge of the restricting 
MHC molecule. For antigen MZ2-F,  only three of the six 
HLA class I specificities of patient MZ2, namely A1, B37, 
and Cw*0601, were possible candidates. This came from the 
finding that subline MZ2-MEL.3.1, which had lost the HLA- 
A29, B'4403,  and Cw'1601 genes, was still lysed by CTL 
76/6 (6,  11, 20). 
The library was divided into pools of 100 recombinant 
clones,  and DNA  from each  pool was  cotransfected into 
microcultures of COS-7 cells with either the HLA-A1 gene, 
the HLA-B37 eDNA, or the HLA-Cw*060I eDNA cloned 
in pcDNAI/Amp. 48 h later, we screened the transfectants 
for the expression of antigen MZ2-F by adding CTL 76/6 
to the microcukures and by measuring TNF production after 
18 h. One out of the 500 cDNA pools that were tested proved 
positive when cotransfected with HLA-Cw*0601. By sub- 
doning the bacteria of this pool and repeating the transfec- 
tion and screening procedures outlined above with individual 
plasmid DNA, we obtained several clones that transferred 
the expression of the antigen. The result obtained with rep- 
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Figure  1.  Specific lysis of autologous melanoma cell line MZ2-MEL 
by CTL 76/6. Variant MZ2-MEL.F- was selected in vitro for resistance 
to CTL 76/6.  Control targets  include  the autologous  EBV-transformed 
lymphoblastoid  line MZ2-EBV and the NK-sensitive  line K562.  IGR3- 
MEL is an allogeneic melanoma line expressing GAGE-l~2  and HLA- 
Cw6. Chromium release was measured after 4 h. Results are pooled from 
two representative  experiments. 
resentative cDNA clone 2D6 is shown in Fig. 2. When this 
done was  cotransfected into HeLa  cells with  the HLA- 
Cw*0601 cDNA, it produced stable transfectants that were 
also recognized by CTL 76/6 (Fig.  2). 
This eDNA was 650 bp long and appeared to be full length, 
since it hybridized with a similarly sized band on a Northern 
blot prepared with KNA from MZ2-MEL (Fig.  3). Its se- 
quence did not show significant  homology with any gene 
reported in data banks, and this new gene was named GAGE. 
It contained an open reading frame coding for a protein of 
138 amino adds. 
The expression of gene GAGE was analyzed by Northern 
blot with RNA from various tissues.  No GAGE mRNA 
was detected in the normal tissues that were tested, but it 
was found in a  number of mdanoma lines  derived from 
different patients (Fig. 3). It appeared therefore that expres- 
sion of antigen MZ2-F results from the activation in mda- 
noma ceils of a gene that is silent in normal tissues. 
The GAGE Gene Family.  By hybridizing 5,000 dones 
of the MZ2-MEL eDNA library with the GAGE eDNA, 
we obtained 20 other eDNA dones carrying five new ho- 
mologous sequences that were 80-98% identical to the GAGE 
eDNA. Accordingly, we renamed GAGE-I  the gene corre- 
sponding to our first eDNA and named the homologous se- 
quences GAGE-2-6. An alignment of the six eDNA sequences 
is shown in Fig. 4. They differ mainly by single nucleotide 
substitutions scattered  throughout the sequence.  This lea- 
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Figure  2.  Stimulation of CTL 76/6 by cells transfected with the HLA- 
Cw.0601 eDNA and with eDNA 2196. COS-7 cells were transiently trans- 
fected with the indicated eDNA cloned in pcDNAI/Amp. HeLa cells were 
stably transfected with the indicated eDNA. The production of TNF by 
CTL 76/6 was measured after 18 h of coculture with the transfi.-cted cells 
by testing toxicity of the supernatants for TNF-seasitive cells WEH1164.13. 
Control stimulator cells included autologous MZ2-MEL and variant MZ2- 
MEL.F-, which was selected in vitro for resistance to CTL 76/6. The 
production of TNF by CTL 76/6 was inhibited  in the presence of mAb 
W6/32,  which binds  to all HLA class I molecules. 
691  Van den Eynde Figure  3.  Northern blot analysis of the expression of gene GAGE. Each 
lane  contains  10 #g of total  RNA  of the calls indicated  on top.  MZ2- 
MEL.3.0 is a done derived from melanoma MZ2-MEL.  MZ2-CTL.82/30 
is a CTL done derived from patient  MZ2.  LB34-MEL,  MI13443-MEL, 
MI10221-MEL,  LB33-MEL,  and SK33-MEL  are mdanoma lines derived 
from other  patients.  Hybridizations were  performed  successively  with 
GAGE cDNA 2D6 and with a ~-actin probe. A series of other mdanoma 
lines were tested similarly and several of them expressed the GAGE mes- 
sage  (not  shown). 
ture makes it unlikely that the different CAGE cDNA result 
from alternative splidng of distinct exons of a single gene, 
but some of them could correspond to different alleles of the 
same gene, so that the actual number of GAGE genes may 
not exceed 3. 
As shown in Fig.  4,  a sequence of 143 nudeotides that 
is located near the termination codon of the GAGE-1 coding 
sequence is absent in the other GAGE cDNA.  Because of 
this insertion,  the GAGE-1 putative protein is 20-22 amino 
acids longer  than the five other predicted proteins (Fig. 5). 
The first 35 bases of this stretch (nudeotide 376-410) show 
significant homologies with Alu repeats, and could therefore 
result from the lack of splidng of an intron (33).  However, 
the sequence of a genomic GAGE done suggests  that the 
GAGE-1  stretch rather corresponds to an additional exon that 
is homologous to a small region of an intron of the other 
GAGE genes.  A  similar situation  has been observed with 
the genes MACE-1  and MACE-2  (34). 
Identification of  the  Antigenic  Peptide Encoded by  Gene 
GAGE.  To identify the GAGE-I;-encoded peptide presented 
by HLA-Cw*0601  to anti-MZ2-F CTL, we generated pro- 
gressive deletions  from  the 3' end of the GAGE-1  cDNA 
by digestion  with exonuclease III. Plasmids containing  the 
truncated cDNA were then cotransfected into COS-7 cells 
with the HLA-Cw'0601  cDNA,  and the transfected cells 
were tested for recognition  by the CTL in a TNF produc- 
tion assay. The smallest truncated cDNA that was positive 
contained the first 168 nucleotides of GAGE-1.  Since the open 
reading frame started in position 49, this result localized the 
peptide in the first 40 amino adds of the protein. A minigene 
GAGE I  ........................  CT~CG  TCC~ACTC~TT~CCTCTACTGAGATTCA  36 
GAG~  4  ........  CGCC~CC.~AG  C'~'O~CAG~CCTG~G~TTCC~CG  ~CCC-~ACTCTTTTTCC~CZAC~GAT~rCA  ;0 
VD~ 44  VDE 18 ￿9  ￿9 
~o~  ~  TC~G~TATGACT~S~r  TCGACC---T~TC~SCCTAGACC~OACGC  TAC~TAGAOCCTCCTC, A~A~T~CCT  123 
SAGE 2  ~CTST~TG~A~__A~TTSSCGA~GA  TCSACC  TATCGGCCTAC~CC~GACSC  TACGT~A~CTCCTS~TGA~C~CCT  ~S 
~g-3  TTCACACASAT~.._.~TCTCASTA~C-GAAAA  TCGACCTATTATTC~CCTA~ACC~C~  TATSTACA3CCTCC~GTSATTO~CT  ~S0 
GAGE 4  TC~TGTG~TATGAG?~C~3CSA~SA  TC~ACCTATTATT~CCTAC,  ACC~C~CGC TATSTACAGCCTCCT~AAAT~TT~GCCT  ~60 
GAGE-5  TCTSTOT~TATO____AGq'~C~C~A~  TCGACC?A~ATT~CCTAGACCAA~SCGC  TATGTACAGCCTCC~GTC-ATTGC-SCCT  152 
SAng-6  TC'~3TGTGAAATATGAG~CC~C~AAGA  TCGACCTA~ATTC.C.CCTA~ACr  TATGTACAGCCTCCTG~G'~ATTGGOCCT  Z59 
VDs  43 
SAG~ I  A~'C,C~CCr  ~CCAGC~ACA~TG~G~CCA  C~AAC~r  2  ~  3 
OAO~ 2  ATGC~CC~CASTTCAOTSA~GTG  G~CCAGC~CACCT~G~C~CCA  OCA~CTC~CGTCAGGA~CCTSCAGCT~CT  2~8 
GAGg-3  ATGCOGCCCGAGCAGTTCA~TGATG~GTG  GAACCAGC~CACCTO~G~GSC~CCA  GC~CTC~CGTCA~ATCCTGCAGC~CT  2~0 
GAG~ 4  ATSCC~3CCCGAGCAOTTCA~T~TGAAGTS  GAAr  GC~CTr  2~0 
GAG~ S  ATSCC-GCCCGAGCAOTTCAGTGATG~STG  GAAr  GCA~CTC~CGTCAGGATr  2~2 
GAGE 6  ATOC~CCGAC-CAGTTCAGTGAT~GTG  C~CCAGC~CACC~C,  AA~CCA  GC~CTC~CGTCAC~ATr162  249 
OA~E i  CAC~A~aAC~AT~AC~SAGCA~CA  C~C~CG~C~E~ATA~  CA~C~C~SGTCAC~AC~G~C~C~T  ~0~ 
GAGE 2  CAC~GAC.GATGAGGGAGCATCTCCA  GGTC~CCG~GCCTGAAGCTCATA~  CAGGAACAG~TCACCCACAGACTGGGTGT  )~B 
~GE-  3  CAGGAGGGAGA~ATGAGC-GACCATCTGCA CGTC~GGGCCGAAGCCT~GCTGATAGC  CAG~CA~TCACCCACAGAC~TGT  36O 
GAGE 4  CAGGA~A~ATGAC.GGACCATCT~A  GGTCAAGGGCCG~GCCTG~GCTGATAfiC  CAGG~CAGCGTCACCCACAGACTC-GGTGT  340 
GAGE 5  CAGGA~GGATGAC.GGA~ATCT~A  C~3TC~G~CCG~GCCTC~GCTGATAGC  CAOGAACAGGGTCACCCACAGACTGGGTOT  B32 
GAGE-6  CAC-GACC~GAC~TGAC,  C-GA~ATCTGCA GGTC~CC~GCCTGAAGCT~TAGC  CAC.GAACAC.C,  GTCACCCACAGACT~O~T  33S 
VOE Z4 
GAGg  1  ~GT~TG~OA~TC~TSG~CA~AG  ATr  ACOCCTG~G~GAGAT~A~T~CACTAT  3~3 
GAGE 2  ~GTGTG~GA~TCCTGATG~CA~AG  AT~CCCGCC~TCCAGA~A~  ACGCCT~G~G  ........  411 
SAGE 3  GA~TGTG~GATC~Tr162  AT~CCC~CC~CCA~AC~A~  ACSCCTC~AGAAS  ......  ~3 
GAGE-4  ~GTGTG~GA~TCC~AT~CA~G  AT~CCCGCC~TCCA~A~  ACGCr  .........  413 
~GE-  5  GA~T~TG~A~TCC~A~CA~  AT~CCCGCC~TCCAGA~A~TG~  AC~CC~G~G  .........  ~05 
~OE  6  GAGTGTG~GAT~TCC~CA~G  G~CCC~C~TCCAGA~A~TG~  AC~CTG~G~G  .......  412 
aAG~-I  G~GCeCAGAC~A~rC~C~C.~C'I~'ra  A~C~TGCTTCTT~eCT~TCCCCA  C~O~CC~G~GTC~Cre~.~eA~C,".~T  ~e~ 
GAGE-  2  .................................  4it 
~A~  ~  .............................................  413 
CAGE  5  .............................................  405 
GA~E  ~  .................................................  4~ 
SAOE  I  OGC~AGACCG~A~'~TCCTA~CATCT~  TC~CA~C.~TCAC~G~ AG~V,  GACATGCT~TGTTGC~C,  GCTOCT  ~ 
GAGE 2  ....................  G~GC~TCACAGTGTT  ~  AG~OACACGT~TGATOCA~CT  465 
GAGE-  3  ...................  GTG~GC~TCACAGTGTT~  AGNACGTN~TGATGCA~NCT  487 
GAGg.  4  .............. GTG~TCACAGTSTT~  AG~CACGTTG~T~TGCA~CT  467 
GAGE  5  .....................  GTG~GC~TCACAGTGTT ~  AG~GfiCACGTTG~ATGCA~CT~T  459 
GAGE 6  .....................  GTG~GC~TCACAGTGTT~  AG~GACACGTTG~ATGCA~CT~T  *66 
~AGE  1  CCT~TO~,b~TTCTTCATTG~GTTC  TCCC~T~GCTTTACAGCCT~C~C,~X  ~ 
GAGE  2  CCTATG~TTTGTTCATT~TTC  TCCC~T~GCTTTACAGCC~C~C~ 
GAGE-3  CCTATGTT~T~GTTCATT~TTC  TCCC~T~GC~AC~CC~C~  G~ 
GAGE  4  CCTATGTT~TTCATT~TTC  TCCC~T~GC~ACA~C~C~ 
GAGE 5  CCTATGTT~TTCATT~TTC  TCCC~T~ACA~C~CTGC~  o~ 
GAGE  6  CCTATGTT~CA~TTC TCCC~T~T~ACA~CTTCTGC~ 
54~ 
538 
560 
540 
532 
539 
Figure  4.  Alignment of the nudeotide sequences  of the  six GAGE 
cDNA.  Bold lines  indicate  the regions  that  are conserved  in the six se- 
quences.  The initiation and termination  codons are underlined.  Primers 
VDE44, VDE18, VDE43, and VDE24 used for the analysis of GAGE ex- 
pression  by PCR are indicated  by arrows. The nudeotide sequences  of 
the six GAGE cDNA are available from EMBL/Genbank/DDBJ  under 
accession  numbers  U19142,  U19143,  U19144,  U19145,  U19146,  and 
U19147. 
encoding only the first 23 amino acids of GAGE-1 was syn- 
thesized by PCK, cloned into plasmid pcDNA3, and tested 
similarly. It conferred expression of the antigen.  Two over- 
lapping synthetic peptides containing residues 1-15 and 8-23 
were synthesized and tested for their ability to render COS-7 
cells, which had been transfected with the HLA-Cw*0601 
cDNA, capable of stimulating  the release of TNF by CTL 
76/6.  The second peptide was effective. Several peptides of 
nine  residues induded  in  this  peptide  were  tested,  and 
antigenic  peptide 
GAGE  -  1  MS  -  WRGR  S  T  -  yR  pRpRRYVE  p  pEMI GP~PEQFSDK'V~PATPEEGEPATQ  RQDpAAAQEG  EDEGASAGQG  pK  p  EA  73 
~GE-2  MS  ~GRST  -yRpRp~pp~I  G~PEQFSD~PATPE~EPA~  RQDp~Q~ED~ASA~GpKp~  '73 
GAGE  3  MNLSRGKSTYYWPRpRRYVQpPEVI  GP~PEQFSDEVEpATPEEGEPATQ  RQDpAAAQEGEDEGASAGQGPKpEA  75 
GAGE  4  MS-%gnRGRST'f~PRpRRYVQPp~I  Gp~I~pEQFSDE~/KPATpEEGEpATQ RQDpAA.KQ~EDD~ASAGQGPKpKA  74 
GAGE  -  5  M  S  -  WRGR  STYYW  pR  pR  RYVQ  p  pK'VI  Gp~PEQF  SDEV~  PATpEEGEPATQ RQDpAA.AQ  BG  ED  EGASAGQG  pKpKA  74 
GAGE-6  MS-WRGRSTYYWpRPRRYVQpPEVI  GpMRPEQFSDEVEPATpEEGEPATQ  RQDpAAAQEGKDEGASAGQGPKpEA  74 
GAGE-  1  D  SQ  EQGH  pQTGC  EC  EDG  PDGQ~P  pNpEEV~TPE  E~  SHYVAQTG  I  LW  L  L~CF  LNL  S  P  ILK  P  138 
GAGE-2  H  SQEQGH  pQTGC  EC  EDGpDGQ  E~IDp  pNFEED'KTPE  EGEK  Q  SQC  .................  116 
~GE  3  DSQEQOH  P~  EC~G  ~Q~P PNP~TPE~EK  Q$~  ..............  i~8 
GAGE-  4  D  SQEQGH  PQTCC  ECF/)GPDGQ~qDp pNp  EK'VKT  p  EEGEKQS  QC  ................  117 
GAGE  5  DSQ  EQGH  PQTGC  ECEDGpDGQEMDp PN  pEEVKT  P  EEGEKQS  QC  ...............  i19 
GAGE-  6  DSQ  EQ~ pQTGC  ECEDG  pDGQEVDp  pN  pEEVKTp  EEG  EKQ  S  QC  ..............  i17 
Figure  5.  Alignment of the protein sequences encoded by the six GAGE 
cDNA.  Bold lines  indicate  the regions  that  are conserved  in the six se- 
quences.  The antigenic  peptide  derived from the GAGE-1 and GAGE-2 
proteins  is underlined. 
692  Gene  GAGE Encodes  a Human Tumor Antigen Recognized by T  Lymphocytes two  overlapping  nonamers,  namely  TYRPRPRRY  and 
YRPRPRRYV, were positive.  We then synthesized the oc- 
tameric peptide common to the two nonamers and the deca- 
meric peptide containing both. The four peptides were com- 
pared  for their ability to  sensitize  HLA-Cw*0601 + EBV 
lymphoblastoid cells to lysis by CTL 76/6 (Fig. 6). Octamer 
YRPRPRRY was found to be the optimal peptide. Half  max- 
imal lysis was obtained at a peptide concentration of ,o100 
nM. The two nonamers were one order of magnitude less 
efficient and the decamer was even less efficient.  Another 
anti-MZ2-F CTL clone derived from a different blood sample 
of patient MZ2 also lysed HLA-Cw*0601 + lymphoblastoid 
cells pulsed with peptide YKPRPRKY (data not shown). 
The gene GAGE-2 codes for the same antigenic peptide 
as GAGE-l, but the homologous peptides encoded by GAGE- 
3-6 have tryptophan instead of arginine in position 2 (Fig. 
5).  When  transfected into  COS-7  cells  with  the  HLA- 
Cw*060I cDNA, only GAGE-1 and GAGE-2 cDNA were 
able to confer recognition by CTL 76/6, showing that the 
arginine in position 2 is an essential element of the MZ2-F 
antigenic peptide (Fig.  7). 9 of the 21 GAGE cDNA were 
either GAGE-1  or GAGE-2 sequences. 
Expression of  GAGE Genes.  The expression of the GAGE 
genes was tested in a panel of normal tissues by reverse tran- 
scription PCR (RT-PCK) 1 using primers common to the 
six GAGE sequences. We found no expression in any normal 
adult tissue except testis (Table 1). With another set of primers 
that amplified only GAGE-I  and GAGE.2, we found that 
a significant proportion of tumors of various histological types 
express  at least  one of these genes (Table  1).  The highest 
proportions of positive tumors were found among sarcomas 
(25%), melanomas (24%), non-small cell lung carcinomas 
(19%),  head and neck tumors (19%),  and testicular semi- 
nomas (five out of six), but the genes are also expressed  in 
bladder tumors and breast tumors. No expression was found 
in colorectal carcinomas and renal cell carcinomas. Melanoma 
line IGR3-MEL, which expresses GAGE-I~2 and HLA-Cw6, 
triggered TNF release by CTL 76/6 (data not shown) and 
was lysed by it (Fig.  1). 
Discussion 
Two members of the GAGE gene family, GAGE-1  and 
GAGE-2, code for a tumor-specific antigenic peptide presented 
to CTL by HLA-Cw*0601. Previous  results obtained with 
mouse tumors revealed two mechanisms that can produce 
such antigens. One is the occurrence of a point mutation 
(35-37);  the other is the activation in the tumor of a gene 
that is silent in normal cells (16). For GAGE,  all our evi- 
dence supports the second mechanism. GAGE genes are ex- 
pressed  in a number of tumors, but not in normal tissues, 
except  the testis.  Furthermore,  the fact that two distinct 
' Abbreviation used i, this paper: RT-PCR, reverse transcription PCR. 
￿9  YRPRPRRY 
60  O  TYRPRPRRY 
￿9  YRPRPRRYV 
50  [] TYRPRPRRYV 
40  (  F + 
,~  ~ 
I  I  I  I  I  I 
10  "1  100  101  102  103  104 
Peptlde  conoentratlon  (nM) 
Figure  6.  Lysis  by CTL 76/6 of HLA-Cw*0601  + cells pulsed with 
GAGE-encoded peptides. Chromium-hbded HLA-Cw*0601  +  EBV- 
transformed lymphoblastoid  cells (LB33-EBV) were pulsed 30 min with 
the indicated  peptides at various concentrations  before  addition  of CTL 
76/6 at an E/T ratio of 10. Chromium  release was measured after  4 h. 
The arrow indicates  the level of lysis of MZ2.MEL  cells (F +) at the same 
E/T ratio. Similar  results  were  obtained  when  autologous  lymphoblastoid 
cells MZ2-EBV were used as peptide-pulsed target cells. 
members of the GAGE gene family  code for this antigen rules 
out the possibility that the antigen appeared  by mutation. 
Because of its specific expression in tumors, the GAGE an- 
tigen may constitute a useful target for specific cancer im- 
munotherapy. The expression of GAGE genes in testis, how- 
ever, raises the issue of undesirable auto-immune effects. The 
Stimulator ceils 
MZ2-MEL 
MZ2-MELF"  I 
COS  + HLA-Cw6 
COS + HLA-Cw6  + GAGE-1 
COS + HLA-Cw6  + GAGE-2 
COS + HLA-Cw6  + GAGE-3 
COS + HLA-Cw6  + GAGE-4 
COS + HLA-Cw6  + GAGE-8 
COS + HLA-Gw6  + GAGE-6 
TNF released by CTL 76/6 (pg/ml) 
Figure  7.  Transfection of the GAGE.J-6 cDNA into COS cells. The 
GAGE eDNA were transiently  cotransfected  into COS-7 cells with the 
HLA.Cw*0601 cDNA. CTL 76/6 was added after 24 h and the produc- 
tion of TNF was measured 18 h hter. Control stimulator  cells included 
autologous MZ2-MEL  and variant MZ2-MEL.F-,  which was selected  in 
vitro for resistance to CTL 76/6. 
693  Van den Eynde Table  1.  Expression of GAGE Genes by Normal and  Tumoral  Tissues 
Normal tissues 
Histological type 
Expression  of 
GAGE.I-6* 
Tumors 
Histological type 
Number of tumors expressing 
GAGE-I-6*  GAGE.l~2 s 
Adult tissues 
Adrenal gland 
Benign naevus 
Bone marrow 
Brain 
Breast 
Cerebellum 
Colon 
Heart 
Kidney 
Liver 
Lung 
Melanocytes 
Muscle 
Ovary 
Prostate 
Skin 
Splenocytes 
Stomach 
Testis 
Thymocytes 
Urinary bladder 
Uterus 
Fetal tissues  I 
Fibroblasts 
Brain 
Liver 
Spleen 
Thymus 
Testis  + 
-  Tumor samples 
-  Melanomas primary lesions 
-  metastases 
-  Sarcomas 
-  Lung carcinomas  (NSCLCII 
-  Bladder  tumors  superficial 
-  infiltrating 
-  Head and neck tumors 
-  Mammary carcinomas 
-  Testicular seminomas 
-  Prostatic  carcinomas 
-  Colorectal carcinomas 
-  Leukemias  and Lymphomas 
-  Renal carcinomas 
-  Tumor cell lines 
+ 
-  Melanomas 
-  Sarcomas 
-  Lung carcinomas  NSCLC II 
SCLC** 
Mesotheliomas 
Head and neck tumors 
Mammary carcinomas 
Bladder  tumors 
Colorectal carcinomas 
Leukemias 
Lymphomas 
Renal carcinomas 
5/39  5/39 (13%) 
47/130  36/129 (28%) 
7/24  6/24 (25%) 
18/77  15/77  (19%) 
1/36  1/36 
10/39  8/39 (21%) 
14/59  11/58 (19%) 
18/162  14/162  (9%) 
6/6  5/6 
2/20  2/20 
0/43 
1/71 
0/45 
45/74  40/74  (54%) 
1/4  1/4 
1/2  1/2 
7/24  7/24 (29%) 
5/19  5/19 (26%) 
0/2 
1/4  0/4 
0/3 
5/13  5/13 
3/6  1/6 
0/6 
0/6 
* Expression of genes GAGE-I-6 was tested by RT-PCR on total RNA with sense primer VDE43 and antisense  primer VDE24 (Fig. 4). These 
primers are common to the six GAGE sequences. They are located in different exons and amplify a 201-base product that is not observed when 
genomic DNA is tested. 
* Expression of genes GAGE-l-6 was tested by RT-PCR on total RNA with sense primer VDE18 and antisense  primer VDE24 (Fig. 4). These 
primers amplify  the six GAGE sequences. They  are located in different exons and give a 239-bp product that is not observed  when genomic  DNA is tested. 
s Expression of GAGE-l~2  was tested by RT-PCR on total RNA with sense primer VDE44 and antisense  primer VDE24 (Fig. 4). These primers 
amplify GAGE-I  and GAGE-2, but not GAGE-3-6.  They are located in different exons and give a 244-bp product that is not observed  when genomic 
DNA is tested. 
II NSCLC, non-small cell lung carcinoma. 
I Fetal tissues derived from fetuses older than 20 w. 
"" SCLC, small cell lung carcinoma. 
694  Gene GAGE Encodes a Human Tumor Antigen Recognized by T Lymphocytes testis is an immunoprivileged  site,  however, and germ-line 
cells do not  express MHC class  I molecules and therefore 
should not express antigens recognized by T  cells (38, 39). 
In male mice, it was possible to generate CTL responses against 
a tumor antigen encoded by gene PIA, which is also expressed 
in testis but not in other normal tissues. We observed nei- 
ther inflammation of testicular tissues nor reduction of fer- 
tility (Uyttenhove, C.,  B. Leth6, T.  Boon, and B. Van den 
Eynde, manuscript in preparation).  In our view, it is there- 
fore likely,  but not certain,  that immunization  against  the 
GAGE antigen will not produce autoimmune  effects. 
Tumors expressing GAGE-l~2 and HLA-Cw6 can be iden- 
tified by typing patients for HLA and by testing the expres- 
sion of GAGE-l~2 by RT-PCK amplification on KNA from 
a small tumor sample. Because HLA-Cw*0601 is present in 
16%  of Caucasian  individuals  and 24%  of melanomas ex- 
press GAGE-I or GAGE-2, ,,04%  of all melanomas should 
express this antigen.  This brings to "~51%  the fraction of 
Caucasian  melanoma  patients  eligible for immunotherapy 
directed against  defined tumor  antigens  encoded by genes 
MAGE-1, MAGE-3, BAGE, or GAGE (Table 2). The histo- 
logical distribution of GAGE-positive  tumors is rather similar 
to that of MAGE-1- or MAGE-3-positive tumors.  In view 
of the very high incidence of non-small cell lung cancer,  it 
is noteworthy that 49% of these cancers express at least one 
of the MAGE-I, MAGE-3, BAGE,  GAGE-l,  or GAGE-2 
genes (40). Accordingly, patients with lung cancer represent 
the largest cohort  of patients  that  could benefit from spe- 
cific  immunotherapy  directed  against  antigens  encoded by 
these genes. 
Melanoma lines studied in vitro were found to simultane- 
ously express several antigens recognized by CTL  (20, 41, 
42). Many tumors expressing GAGE-l~2 also express MAGE- 
1, MAGE-3,  or BAGE (data not shown).  Some of the pa- 
tients bearing  such tumors could therefore be immunized 
simultaneously against several antigens encoded by these genes. 
This might ensure a more effective tumor rejection response. 
It should also reduce the emergence of antigen loss variants 
arising by loss of antigen expression, since it is unlikely that 
tumor cells could simultaneously delete or mutate several of 
these genes or lose their expression. Nevertheless, the simul- 
taneous loss of several antigens could still occur after the loss 
of MHC class I molecules. Fortunately, MHC-negative vari- 
ants appear to be highly sensitive to NK cells,  which may 
eliminate these variants (43, 44). In support of this notion, 
Levitsky et al. observed the very frequent emergence of MHC- 
negative variants in immunized mice that had been depleted 
of NK1 + cells before challenge with tumor cells. These vari- 
ants were less frequently observed in mice that had not been 
NK depleted (45). 
To the best of our knowledge, the GAGE peptide is the 
first antigenic peptide presented by HLA-Cw6 that has been 
identified. A consensus motif for binding to HLA-Cw6 was 
proposed by Falk et al. on the basis of peptide elution studies 
(46). A dominant residue of this motif was L at position 9. 
Strong residues were P in position 4, I or L in position 5, 
and V,  I, or L in position 6.  Our peptide does not fit this 
motif.  A  first difference is the presence of tyrosine instead 
of leucine at the COOH terminus of the GAGE peptide. Al- 
though tyrosine was also detected at position 9 in the pool 
of eluted peptides, it was not considered a dominant or strong 
residue.  Another difference is the fact that  the GAGE pep- 
tide that is most effective in vitro is an octamer rather than 
a nonamer,  but this does not prove that the octamer is the 
natural peptide. The cells used by Falk et al. (46) for the pep- 
tide elution expressed the HLA-Cw*0602 allele, which was 
first reported to be distinct from Cw*0601 (47).  However, 
after correction of sequence uncertainties,  the two Cw6 se- 
quences proved identical  (48).  In any case,  allelic  diversity 
could not explain the divergence of the GAGE peptide from 
the proposed motif because the cells used by Falk et al. (46) 
can present the GAGE peptide to CTL 76/6 (data not shown). 
Among the class I binding  antigenic  peptides that  have 
so far been identified in humans, most are presented by HLA-A 
Table  2.  Proportion  of Melanoraas Expressing Antigens Encoded by the MAGE,  BAGE,  or GAGE genes 
Fractions  of melanomas 
Expressing  an antigen  presented by HLA 
Expressing 
Genes  the gene  A1 (26%)*  A2 (49%)  Cw16 (7%)  Cw6 (16%)  Reference 
MAGE-1  36%  9%  3%  8,  11 
MAGE-3  64%  17%  31%  9,  15 
BAGE  22%  2%  6 
GAGE-l~2  24%  4%  this report 
Corrected* total of melanomas expressing  at least one antigen:  51% 
" The frequency of each HLA specificity in Caucasians is indicated in parentheses. 
After correction for melanomas expressing both HLA-A1 and HLA-A2, and for melanomas expressing both MAGE-1 and MAGE-3. 
695  Van den Eynde or HLA-B molecules, and only very few by HLA-C (49-52). 
Since surface expression  of HLA-C molecules was reported 
to be lower than that of HLA-A and HLA-B, this led to 
the suggestion that HLA-C molecules do not contribute 
significandy to antigen presentation (53). However, in MZ2- 
MEL melanoma cells, we have observed that among five an- 
tigens recognized by autologous CTL, three are presented 
by HLA-C molecules, and both HLA-C alleles are involved: 
HLA-Cw*1601 presents a peptide derived from MAGE-1 and 
another derived from BAGE, whereas HLA-Cw*0601 presents 
a GAGE-encoded  antigen (6,  11). 
Like MAGE and RAGE, the GAGE genes form a family 
of very closely related genes. The MAGE family is made up 
of 12 genes,  none of which are expressed  in normal adult 
tissues besides the testis (6, 34).  In addition to these genes 
located in the q27-qter region of the X chromosome, several 
additional  related genes are located  in the p21.3 region of 
the same chromosome (54, 55). Hydrophobic cluster anal- 
),sis of the proteins  encoded by the different MAGE genes 
showed a remarkable conservation of the main hydrophobic 
regions,  suggesting conservation  of function of these pro- 
teins. Higher variation was observed in the promoter region 
of the MAGE genes, and this led to the suggestion that dupli- 
cation of a MAGE gene into a large gene family placed the 
same function under different transcriptional controls,  pos- 
sibly to allow it to occur at a number of very specific times 
and locations (34). The apparent absence of expression in adult 
somatic tissues  and in fetuses  older  than 20 wk raises the 
possibility that MAGE, BAGE, and GAGE gene products 
play a role during early stages of embryonic development. 
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